Fujisawa Pharmaceutical Company, Ltd.

Astellas Pharma Gmbh

Kouji Hattori

Akira Tanaka

Kiyoshi Taniguchi

Osamu Okitsu

Kazunori Tsubaki

Seiichiro Tabuchi

Masanobu Nagano

Masashi Imanishi

Naoaki Fujii

Minoru Sakurai

Yasuyo Tomishima

Daisuke Tanabe

Kenichi Washizuka

Takanobu Araki

Susumu Toda

Shinji Ito

Hiromichi Itani

Fujiko Takamura

Mie Nishio

Satoshi Koyama

Shoko Nakazato

Yutaka Kono

Toshifumi Shiraga

The present invention relates to a compound of the formula [I]: wherein (a), in which &#x2014;Y&#x2014;, R, Rand RareReach as defined in the description, etc., Ris hydrogen, halogen, lower alkyl, hydroxy, etc., Ris hydrogen, lower alkyl or hydroxy(lower)alkyl, Ris hydrogen or an amino protective group,is hydrogen, lower alkyl, cyclo(lower)alkyl, lower R9 alkenyl, &#x2014;Z&#x2014;Ror (b), in which &#x2014;Z&#x2014; is &#x2014;0&#x2014;, &#x2014;S&#x2014;, R&#x2014;SO&#x2014; or &#x2014;SO&#x2014;, and each Ris independently hydrogen, lower alkyl, cyclo(lower)alkyl, etc., and Ris -D-E-R, in which -D- is &#x2014;CONHSO&#x2014; or &#x2014;S0NHCO&#x2014;, E is bond or lower alkylene, and Ris halogen, cyano, carboxy, etc., or a prodrug thereof or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of ulcer, overactive bladder, and the like. 

Aminoalcohol derivatives

The present invention relates to a compound formula [I]: wherein  

The present invention relates to a compound formula[I]: wherein  The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.

The present invention relates to a compound formula [I]:wherein

Heterocyclic compounds of formula (I), wherein R is carboxy or protected carboxy, R is aryl which may have suitable sustituent(s), R is aryl which may have suitable substituent(s), R is hydrogen, lower alkyl, hydroxy or aryl, A is lower alkylene, (a) is (b), etc., &mdash;A &mdash; is (c), etc. and n is 0 or 1, and pharmaceutically acceptable salts thereof which are useful as a medicament.

4.5-diaryloxazole compounds with prostaglandin I2 (PGI2) agonistic activity

Oxazole compounds of formula (I), wherein R is aryl which may be substituted with halogen(s), R is aryl which may be substituted with halogen(s), X is single bond, (a) or SO , R and R are independently hydrogen or suitable substituent, (wherein X is (a), neither R nor R is hydrogen), R and R may be linked together to form (b), (b) is N-containing heterocyclic group which may be substituted with one or more suitable substituent(s), R is hydrogen, etc., A is lower alkylene or single bond, (c) is cyclo(C -C )alkane or cyclo(C -C )alkene, or a pro-drug thereof, or a pharmaceutically acceptable salt thereof, which are useful as medicament.

Oxazole compounds as prostaglandin e2 agonists or antagonists

This invention relates to benzocycloheptene derivatives having novel structure. More particularly, it relates to new benzocycloheptene derivatives and pharmaceutically acceptable salts thereof, their production processes, a pharmaceutical composition containing the same and a use thereof for the manufacture of medicaments.

Benzocycloheptene derivatives

Naphthalene derivatives

Heterocyclic compounds

4,5-diaryloxazole compounds

Oxazole compounds useful as PGE2 agonists and antagonists

Heterocyclic compounds of the formula: ##STR1## whereinR.sup.1 is carboxy or protected carboxy,

4,5-diaryloxazole derivatives

4,5-diaryl oxazole derivatives

A compound or the formula: ##STR1## wherein R.sup.1 is carboxy or protected carboxy, R.sup.2 is hydrogen, hydroxy or protected hydroxy,

Naphthalene derivatives as prostaglandin I.sub.2 agonsists

Growing community of inventors

Osaka, Japan

Kouji Hattori